Skip to main content

STUDY PROTOCOL article

Front. Pharmacol.
Sec. Neuropharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1378081
This article is part of the Research Topic Current Progress and Challenges in Psychopharmacology Research View all 6 articles

Efficacy and safety of fospropofol disodium sedation for same-day bidirectional endoscopy in elderly patients: protocol for a prospective, single-center, randomized, double-blind, noninferiority trial

Provisionally accepted
Zhe Zhao Zhe Zhao 1Xiaofeng Wang Xiaofeng Wang 2Yong Li Yong Li 3Yongchen Cui Yongchen Cui 2Bing Zhang Bing Zhang 3Yu Kang Yu Kang 3Guangming Zhang Guangming Zhang 3Junfeng Zhang Junfeng Zhang 4*
  • 1 Department of Geriatrics, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China
  • 2 Department of Anesthesiology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, Shanghai Municipality, China
  • 3 Department of Anesthesiology, Tongren Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  • 4 Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China

The final, formatted version of the article will be published soon.

    Introduction: Fospropofol disodium is a novel prodrug that has improved pharmacokinetic and pharmacodynamic properties when compared with propofol. This trial aims to compare the efficacy and safety of fospropofol versus propofol sedation for same-day bidirectional endoscopy in elderly patients.This is a prospective, single-center, double-blind, randomized, propofolcontrolled, non-inferiority trial. A total of 256 adult patients aged 65 years or older, who are scheduled for same-day bidirectional endoscopy under sedation, will be randomly allocated, in a 1:1 ratio, to aeither fospropofol group or a propofol group (n=128 in each group). All patients will receive analgesic pre-treatment with sufentanil 5 μg. Two minutes later, an initial bolus dose of fospropofol 6.5 mg/kg or 1.5 mg/kg propofol and supplemental doses of fospropofol 1.6 mg/kg or 0.5 mg/kg propofol will be titrated as needed to achieve target sedation levels during the procedures.The primary outcome is the success rate of same-day bidirectional endoscopy. Secondary outcomes include the time to successful induction of sedation, duration, time to being fully alert, time to patient discharge, endoscopist satisfaction, patient satisfaction, and the top-up frequency and dosage of sedative medications. The safety endpoints consist of adverse events (AEs) concerning cough reflex, gag reflexes, body movement, muscular tremor, and pain on injection. Sedation-related AEs, including episodes of desaturation, severe desaturation (SpO2 < 90%), hypotension, severe hypotension (decrease in MBP ≥30% of baseline), and bradycardia, will also be recorded. Data will be analyzed on an intention-to-treat basis.Discussion: We hypothesize that the efficacy and safety of fospropofol sedation for elderly patients undergoing same-visit bidirectional endoscopy will not be inferior to that of propofol. Our findings will potentially provide a newdaily practice of sedation regimen for same-visit bidirectional endoscopy in elderly patients.

    Keywords: Fospropofol, Propofol, sedation, Elderly, bidirectional endoscopy

    Received: 09 Feb 2024; Accepted: 26 Jul 2024.

    Copyright: © 2024 Zhao, Wang, Li, Cui, Zhang, Kang, Zhang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Junfeng Zhang, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.